MX382970B - Molecula de unión al antígeno trifuncional - Google Patents

Molecula de unión al antígeno trifuncional

Info

Publication number
MX382970B
MX382970B MX2016013218A MX2016013218A MX382970B MX 382970 B MX382970 B MX 382970B MX 2016013218 A MX2016013218 A MX 2016013218A MX 2016013218 A MX2016013218 A MX 2016013218A MX 382970 B MX382970 B MX 382970B
Authority
MX
Mexico
Prior art keywords
antigen
binding molecule
antigenic epitope
binding
specificity against
Prior art date
Application number
MX2016013218A
Other languages
English (en)
Spanish (es)
Other versions
MX2016013218A (es
Inventor
Eugene Zhukovsky
Gall Fabrice Le
Kristina Ellwanger
Markus Eser
Melvyn Little
Michael Weichel
Thorsten Gantke
Uwe Reusch
Original Assignee
Affimed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50478320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX382970(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Affimed Gmbh filed Critical Affimed Gmbh
Publication of MX2016013218A publication Critical patent/MX2016013218A/es
Publication of MX382970B publication Critical patent/MX382970B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2016013218A 2014-04-13 2015-04-12 Molecula de unión al antígeno trifuncional MX382970B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14164523.4A EP2930188A1 (en) 2014-04-13 2014-04-13 Trifunctional antigen-binding molecule
PCT/EP2015/057919 WO2015158636A1 (en) 2014-04-13 2015-04-12 Trifunctional antigen-binding molecule

Publications (2)

Publication Number Publication Date
MX2016013218A MX2016013218A (es) 2017-05-19
MX382970B true MX382970B (es) 2025-03-12

Family

ID=50478320

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013218A MX382970B (es) 2014-04-13 2015-04-12 Molecula de unión al antígeno trifuncional

Country Status (13)

Country Link
US (2) US20170037128A1 (cg-RX-API-DMAC7.html)
EP (2) EP2930188A1 (cg-RX-API-DMAC7.html)
JP (1) JP6635940B2 (cg-RX-API-DMAC7.html)
KR (1) KR102392598B1 (cg-RX-API-DMAC7.html)
CN (1) CN106661108A (cg-RX-API-DMAC7.html)
AU (1) AU2015249006B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016023362A2 (cg-RX-API-DMAC7.html)
CA (1) CA2945053A1 (cg-RX-API-DMAC7.html)
DK (1) DK3131928T4 (cg-RX-API-DMAC7.html)
MX (1) MX382970B (cg-RX-API-DMAC7.html)
RU (1) RU2753882C2 (cg-RX-API-DMAC7.html)
SI (1) SI3131928T2 (cg-RX-API-DMAC7.html)
WO (1) WO2015158636A1 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113549153A (zh) 2014-05-29 2021-10-26 宏观基因有限公司 三特异性结合分子和其使用方法
JP6839101B2 (ja) * 2015-06-15 2021-03-03 ヌマブ セラピューティクス アクチェンゲゼルシャフト ヘテロ二量体多重特異性抗体フォーマット
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
KR20250089564A (ko) 2017-02-08 2025-06-18 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
KR20190120782A (ko) 2017-02-20 2019-10-24 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US20200362054A1 (en) * 2017-11-21 2020-11-19 Brian Granda Trispecific binding molecules against tumor-associated antigents and use thereof
CA3079363A1 (en) * 2017-11-21 2019-05-31 Innate Pharma Multispecific antigen binding proteins
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
PE20210375A1 (es) 2018-02-08 2021-03-02 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019175368A1 (en) * 2018-03-14 2019-09-19 Affimed Gmbh Bispecific egfr/cd16 antigen-binding protein
CN111527108A (zh) * 2018-03-27 2020-08-11 西雅图免疫公司 制导和导航控制蛋白的制造和使用方法
EP3802609A2 (en) 2018-05-24 2021-04-14 Janssen Biotech, Inc. Psma binding agents and uses thereof
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
BR112021002276A2 (pt) 2018-08-08 2021-05-04 Dragonfly Therapeutics, Inc. proteínas de ligação a nkg2d, cd16 e um antígeno associado ao tumor
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
PL3843757T3 (pl) 2018-08-27 2024-08-05 Affimed Gmbh Kriokonserwowane komórki nk wstępnie obciążone konstruktem przeciwciała
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
MA55717A (fr) 2019-04-19 2022-02-23 Janssen Biotech Inc Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
JOP20210309A1 (ar) 2019-05-21 2023-01-30 Novartis Ag جزيئات ربط بـ cd19 واستخدامتها
CA3160927A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
US12157771B2 (en) 2020-05-06 2024-12-03 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
JP2023545099A (ja) 2020-10-08 2023-10-26 アフィメド ゲーエムベーハー 三重特異性バインダー
CA3200317A1 (en) * 2020-11-06 2022-05-12 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
EP4247850A1 (en) 2020-11-20 2023-09-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
JP2024504758A (ja) 2021-01-28 2024-02-01 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ結合タンパク質及びその使用
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
EP4376958A1 (en) 2021-07-30 2024-06-05 Affimed GmbH Duplexbodies
CN114044822B (zh) * 2021-10-28 2023-06-27 杭州博茵生物技术有限公司 血清淀粉样蛋白a抗体的重链和轻链可变区、抗体及运用
CN114316060B (zh) * 2021-12-15 2023-06-13 北京市肿瘤防治研究所 抗人cd19与cd206双特异性抗体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
UA40577C2 (uk) * 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
WO1998003670A1 (en) * 1996-07-23 1998-01-29 Tanox Pharma B.V. Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
ES2276735T3 (es) * 2001-09-14 2007-07-01 Affimed Therapeutics Ag Anticuerpos fv multimericos de cadena sencilla en tandem.
PL372144A1 (en) * 2001-12-26 2005-07-11 Immunomedics, Inc. Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains
PL1673398T3 (pl) * 2003-10-16 2011-05-31 Amgen Res Munich Gmbh Multispecyficzne deimmunizowane cząsteczki wiążące CD3
JP5399712B2 (ja) * 2005-12-21 2014-01-29 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 可溶性ｃｅａに対する抵抗性を有する医薬組成物
BRPI0910482A2 (pt) * 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
MX2011011925A (es) * 2009-05-27 2011-12-06 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos.
EP2332994A1 (en) * 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
WO2012054748A2 (en) * 2010-10-22 2012-04-26 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway

Also Published As

Publication number Publication date
WO2015158636A1 (en) 2015-10-22
DK3131928T3 (da) 2020-02-24
RU2016138347A3 (cg-RX-API-DMAC7.html) 2018-12-04
AU2015249006A1 (en) 2016-10-20
JP2017513476A (ja) 2017-06-01
AU2015249006B2 (en) 2020-10-29
US20170037128A1 (en) 2017-02-09
EP3131928B1 (en) 2019-11-20
JP6635940B2 (ja) 2020-01-29
WO2015158636A8 (en) 2016-11-17
DK3131928T4 (da) 2023-05-30
CA2945053A1 (en) 2015-10-22
BR112016023362A2 (pt) 2018-03-27
RU2753882C2 (ru) 2021-08-24
EP3131928A1 (en) 2017-02-22
US20220048994A1 (en) 2022-02-17
SI3131928T1 (sl) 2020-04-30
RU2016138347A (ru) 2018-05-14
CN106661108A (zh) 2017-05-10
MX2016013218A (es) 2017-05-19
KR102392598B1 (ko) 2022-04-29
KR20160143739A (ko) 2016-12-14
SI3131928T2 (sl) 2023-05-31
EP2930188A1 (en) 2015-10-14
EP3131928B2 (en) 2023-04-05

Similar Documents

Publication Publication Date Title
MX382970B (es) Molecula de unión al antígeno trifuncional
CY1123397T1 (el) Συνθεσεις που περιλαμβανουν συνδυασμο ιπιλιμουμαμπης και νιβολουμαμπης
CO2017001994A2 (es) Compuestos activos hacia bromodominios
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
EA201792414A1 (ru) Антитела против cd166, активируемые антитела против cd166 и способы их применения
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
MX2018014154A (es) Polinucleotidos moduladores.
CL2017001736A1 (es) Anticuerpos anti-cd47 y uso de los mismos.
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
BR112018005779A2 (pt) repressores de htt e usos dos mesmos
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
BR112017001579A2 (pt) anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
BR112016029013A2 (pt) aperfeiçoamento em composição nasal e método de utilização do mesmo
CL2015001772A1 (es) Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma.
MX377089B (es) Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral.
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
UY35747A (es) Derivados sustituidos de fenilalanina
MX2016010059A (es) Anticuerpos útiles en la inmunización pasiva contra la gripe y composiciones, combinaciones y métodos para utilizarlos.
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
MX392761B (es) Anticuerpos anti-influenza b neutralizantes y usos de los mismos.